OTCMKTS:EVTCY Evotec (EVTCY) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free EVTCY Stock Alerts $4.83 +0.06 (+1.26%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$4.80▼$4.9650-Day Range$4.52▼$7.8752-Week Range$14.22▼$26.57Volume81,278 shsAverage Volume2,407 shsMarket Capitalization$1.59 billionP/E Ratio11.77Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get Evotec alerts: Email Address Ad Crypto 101 MediaMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look: Claim your free seat by clicking here now. About Evotec Stock (OTCMKTS:EVTCY)Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Read More EVTCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVTCY Stock News HeadlinesApril 24, 2024 | finance.yahoo.comEQEvotec SE Appoints Dr Christian Wojczewski as Chief Executive OfficerApril 23, 2024 | markets.businessinsider.comEQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive OfficerMarch 6, 2024 | finanznachrichten.deEvotec SE: Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The ClinicJanuary 10, 2024 | finanznachrichten.deEvotec SE: Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD TherapiesJanuary 4, 2024 | markets.businessinsider.comEvotec, Owkin Anounce A.I.-Powered Collaboration In Oncology, Immunology, And InflammationNovember 12, 2023 | finance.yahoo.comEvotec SE (NASDAQ:EVO) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | markets.businessinsider.comEQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate updateOctober 5, 2023 | finance.yahoo.com65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in SingaporeSeptember 27, 2023 | finance.yahoo.comEvotec SE: Launch of Partnering Agreement to Strengthen Biotech Innovators in Shared R&D EconomySeptember 21, 2023 | finance.yahoo.comEvotec SE (EVO) Stock Historical Prices & Data - Yahoo FinanceMay 30, 2023 | finance.yahoo.comIs There Now An Opportunity In Evotec SE (ETR:EVT)?May 14, 2023 | finance.yahoo.comEvotec SE (ETR:EVT) Shares Could Be 37% Below Their Intrinsic Value EstimateMay 13, 2023 | finanznachrichten.deEvotec SE: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023May 12, 2023 | investing.comEvotec SE ADR (EVO) Earnings Dates & ReportsMay 10, 2023 | investing.comEvotec SE ADR (EVO)May 9, 2023 | finanznachrichten.deEvotec SE: Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial ManufacturingApril 10, 2023 | finance.yahoo.comEvotec SE Provides Update on Cyber AttackFebruary 10, 2023 | finanznachrichten.deEvotec SE: Evotec Receives € 150 m Loan from European Investment BankJanuary 31, 2023 | markets.businessinsider.comEQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionDecember 22, 2022 | ca.finance.yahoo.comWith 47% ownership, Evotec SE (ETR:EVT) has piqued the interest of institutional investorsDecember 17, 2022 | finanznachrichten.deEvotec SE: Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers SquibbSeptember 21, 2022 | finanznachrichten.deEvotec SE: Just - Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies ProgramSeptember 20, 2022 | markets.businessinsider.comEvotec: US Unit Gets $49.9 Mln Antibodies Contract From U.S. Department Of DefenseSeptember 17, 2022 | finanznachrichten.deEvotec SE: Evotec Initiates Ground-Breaking for New Biologics Facility J.POD Toulouse, FranceAugust 13, 2022 | seekingalpha.comEvotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call TranscriptSee More Headlines Receive EVTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:EVTCY CUSIPN/A CIK1412558 Webwww.evotec.com Phone(494) 056-0810Fax49-40-5608-1222Employees3,572Year Founded1993Profitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E Ratio11.77 Forward P/E RatioN/A P/E GrowthN/ANet Income$7.14 million Net Margins20.85% Pretax Margin23.90% Return on Equity16.02% Return on Assets7.81% Debt Debt-to-Equity Ratio0.53 Current Ratio2.57 Quick Ratio2.50 Sales & Book Value Annual Sales$572.16 million Price / Sales2.78 Cash Flow$0.05 per share Price / Cash Flow105.53 Book Value$2.52 per share Price / Book1.91Miscellaneous Outstanding Shares330,221,000Free FloatN/AMarket Cap$1.59 billion OptionableNot Optionable Beta0.98 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesWerner LanthalerChief Executive OfficerCraig L. JohnstoneChief Operating Officer & Member-Management BoardEnno SpillnerChief Financial OfficerCord E. DohrmannChief Scientific OfficerVolker BraunSVP, Head-Investor Relations & ESGKey CompetitorsViking TherapeuticsNASDAQ:VKTXIonis PharmaceuticalsNASDAQ:IONSCytokineticsNASDAQ:CYTKSummit TherapeuticsNASDAQ:SMMTOrganon & Co.NYSE:OGNView All Competitors EVTCY Stock Analysis - Frequently Asked Questions How have EVTCY shares performed in 2024? Evotec's stock was trading at $11.73 on January 1st, 2024. Since then, EVTCY stock has decreased by 58.9% and is now trading at $4.8250. View the best growth stocks for 2024 here. When did Evotec's stock split? Shares of Evotec split on Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly created shares were distributed to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. How do I buy shares of Evotec? Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Evotec have any subsidiaries? The following companies are subsidiares of Evotec: Aptuit, Bionamics GmbH, Cell Culture Service GmbH, Central Glass Germany, Central Glass Germany. GmbH, Compound Focus, Cyprotex, Develogen AG, Euprotec, Evotec (India) Private Ltd, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, KINAXO Biotechnologies, Oxford Asymmetry International, RENOVIS, and Rigenerand Srl.Read More This page (OTCMKTS:EVTCY) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.